Exact Mass: 455.3763

Exact Mass Matches: 455.3763

Found 137 metabolites which its exact mass value is equals to given mass value 455.3763, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Arachidyl carnitine

3-(Icosanoyloxy)-4-(trimethylammonio)butanoic acid

C27H53NO4 (455.3974)


Arachidyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] Arachidyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).

   

9-methylnonadecanoylcarnitine

3-[(9-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


9-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 9-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

10-methylnonadecanoylcarnitine

3-[(10-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


10-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 10-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 10-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 10-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

14-methylnonadecanoylcarnitine

3-[(14-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


14-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 14-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 14-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 14-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

12-methylnonadecanoylcarnitine

3-[(12-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


12-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 12-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 12-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 12-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-methylnonadecanoylcarnitine

3-[(7-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


7-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-methylnonadecanoylcarnitine

3-[(6-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


6-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 6-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

13-methylnonadecanoylcarnitine

3-[(13-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


13-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 13-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 13-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 13-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-methylnonadecanoylcarnitine

3-[(8-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


8-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

16-methylnonadecanoylcarnitine

3-[(16-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


16-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 16-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 16-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 16-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-methylnonadecanoylcarnitine

3-[(5-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


5-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

11-methylnonadecanoylcarnitine

3-[(11-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


11-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 11-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 11-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 11-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

15-methylnonadecanoylcarnitine

3-[(15-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


15-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 15-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 15-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 15-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

18-methylnonadecanoylcarnitine

3-[(18-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


18-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 18-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 18-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 18-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

17-methylnonadecanoylcarnitine

3-[(17-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


17-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 17-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 17-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 17-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-methylnonadecanoylcarnitine

3-[(3-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


3-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-methylnonadecanoylcarnitine

3-[(4-methylnonadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


4-methylnonadecanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methylnonadecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-methylnonadecanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 4-methylnonadecanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4alpha-carboxy-stigmasta-7,24(241)-dien-3beta-ol

(2S,5S,6S,15R)-5-hydroxy-2,15-dimethyl-14-[(2R,5Z)-5-(propan-2-yl)hept-5-en-2-yl]tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-9-ene-6-carboxylate

C30H47O3 (455.3525)


4alpha-carboxy-stigmasta-7,24(241)-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-stigmasta-7,24(241)-dien-3beta-ol can be found in a number of food items such as sorrel, blackcurrant, nutmeg, and purslane, which makes 4alpha-carboxy-stigmasta-7,24(241)-dien-3beta-ol a potential biomarker for the consumption of these food products.

   

N-Benzyl-15-tetracosenamide

N-Benzyl-15-tetracosenamide

C31H53NO (455.4127)


   

1-(3-hydroxyspirosol-5-en-28-yl)ethanone

1-(3-hydroxyspirosol-5-en-28-yl)ethanone

C29H45NO3 (455.3399)


   

Acetylsolasodine

Acetylsolasodine

C29H45NO3 (455.3399)


   
   
   

(Z)-N-benzyltetracos-15-enamide|N-benzyl-15Z-tetracosenamide

(Z)-N-benzyltetracos-15-enamide|N-benzyl-15Z-tetracosenamide

C31H53NO (455.4127)


   

serratezomine D

serratezomine D

C29H49N3O (455.3875)


   

(3beta,16beta,17alpha,20S)-17-methyl-20-[(2S,5S)-5-methylpiperidin-2-yl]-18-norpregna-5,12-diene-3,16-diol 3-acetate|3-O-acetylveralkamine

(3beta,16beta,17alpha,20S)-17-methyl-20-[(2S,5S)-5-methylpiperidin-2-yl]-18-norpregna-5,12-diene-3,16-diol 3-acetate|3-O-acetylveralkamine

C29H45NO3 (455.3399)


   

3-hydroxylup-20(29)-en-28-amide|betulinic acid amide|betulinic amide

3-hydroxylup-20(29)-en-28-amide|betulinic acid amide|betulinic amide

C30H49NO2 (455.3763)


   

calyciphylline D

calyciphylline D

C29H45NO3 (455.3399)


   

agelasimine-B

agelasimine-B

C27H45N5O (455.3624)


   

acetylleptinidine

acetylleptinidine

C29H45NO3 (455.3399)


   

MLS000736975-01!

MLS000736975-01!

C29H45NO3 (455.3399)


   

N-Acetylsolasodine

N-Acetylsolasodine

C29H45NO3 (455.3399)


Annotation level-1

   

O-Acetylsolasodine

O-Acetylsolasodine

C29H45NO3 (455.3399)


Annotation level-1

   

Spirosol-5-en-3-yl acetate

Spirosol-5-en-3-yl acetate

C29H45NO3 (455.3399)


Origin: Plant; Formula(Parent): C29H45NO3; Bottle Name:O-Acetylsolasodine; PRIME Parent Name:O-Acetylsolasodine; PRIME in-house No.:V0335; SubCategory_DNP: Steroidal alkaloids, Solanaceous alkaloids

   

Ecalcidene

(5Z,7E)-(1S,3R)-24-oxo-25-aza-26,27-propano-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol

C29H45NO3 (455.3399)


   

Arachidyl carnitine

Arachidyl carnitine

C27H53NO4 (455.3974)


   

CAR 20:0

3-(icosanoyloxy)-4-(trimethylazaniumyl)butanoate

C27H53NO4 (455.3974)


   

NA 31:5

N-15Z-tetracosenoyl-benzylamine

C31H53NO (455.4127)


   

Hexadecyltrimethylammonium p-toluenesulfonate

Hexadecyltrimethylammonium p-toluenesulfonate

C26H49NO3S (455.3433)


   

4alpha-carboxy-stigmasta-7,24(241)-dien-3beta-ol

(2S,5S,6S,15R)-5-hydroxy-2,15-dimethyl-14-[(2R,5Z)-5-(propan-2-yl)hept-5-en-2-yl]tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-9-ene-6-carboxylate

C30H47O3 (455.3525)


4alpha-carboxy-stigmasta-7,24(241)-dien-3beta-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4alpha-carboxy-stigmasta-7,24(241)-dien-3beta-ol can be found in a number of food items such as sorrel, blackcurrant, nutmeg, and purslane, which makes 4alpha-carboxy-stigmasta-7,24(241)-dien-3beta-ol a potential biomarker for the consumption of these food products. 4α-carboxy-stigmasta-7,24(241)-dien-3β-ol is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 4α-carboxy-stigmasta-7,24(241)-dien-3β-ol can be found in a number of food items such as sorrel, blackcurrant, nutmeg, and purslane, which makes 4α-carboxy-stigmasta-7,24(241)-dien-3β-ol a potential biomarker for the consumption of these food products.

   

Oleanolate

Oleanolate

C30H47O3- (455.3525)


A monocarboxylic acid anion that is the conjugate base of oleanolic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   

4alpha-carboxy-stigmasta-7,24(241)-dien-3beta-ol

4alpha-carboxy-stigmasta-7,24(241)-dien-3beta-ol

C30H47O3- (455.3525)


   
   

Urs-12-en-28-oic acid, 3-hydroxy-, (3beta)-

Urs-12-en-28-oic acid, 3-hydroxy-, (3beta)-

C30H47O3- (455.3525)


   

(3S,4S,10S,13R)-3-hydroxy-10,13-dimethyl-17-[(Z,2R)-5-propan-2-ylhept-5-en-2-yl]-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-4-carboxylate

(3S,4S,10S,13R)-3-hydroxy-10,13-dimethyl-17-[(Z,2R)-5-propan-2-ylhept-5-en-2-yl]-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-4-carboxylate

C30H47O3- (455.3525)


   

9-methylnonadecanoylcarnitine

9-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

7-methylnonadecanoylcarnitine

7-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

6-methylnonadecanoylcarnitine

6-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

8-methylnonadecanoylcarnitine

8-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

5-methylnonadecanoylcarnitine

5-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

3-methylnonadecanoylcarnitine

3-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

4-methylnonadecanoylcarnitine

4-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

10-methylnonadecanoylcarnitine

10-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

14-methylnonadecanoylcarnitine

14-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

12-methylnonadecanoylcarnitine

12-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

13-methylnonadecanoylcarnitine

13-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

16-methylnonadecanoylcarnitine

16-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

11-methylnonadecanoylcarnitine

11-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

15-methylnonadecanoylcarnitine

15-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

18-methylnonadecanoylcarnitine

18-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

17-methylnonadecanoylcarnitine

17-methylnonadecanoylcarnitine

C27H53NO4 (455.3974)


   

(R)-icosanoylcarnitine

(R)-icosanoylcarnitine

C27H53NO4 (455.3974)


An O-acyl-L-carnitine in which the acyl group is specified as icosanoyl.

   

3beta-Hydroxy-lanosta-8, 24-dien-26-oate

3beta-Hydroxy-lanosta-8, 24-dien-26-oate

C30H47O3- (455.3525)


   

4alpha-Carboxy-4beta,14alpha-dimethyl-9beta,19-cyclo-5alpha-cholest-24-en-3beta-ol

4alpha-Carboxy-4beta,14alpha-dimethyl-9beta,19-cyclo-5alpha-cholest-24-en-3beta-ol

C30H47O3- (455.3525)


   

(2E)-20-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]icos-2-enoate

(2E)-20-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]icos-2-enoate

C26H47O6- (455.3372)


   

(E,19R)-19-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxyicos-2-enoate

(E,19R)-19-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxyicos-2-enoate

C26H47O6- (455.3372)


   

NAGly 10:0/14:0

NAGly 10:0/14:0

C26H49NO5 (455.3611)


   

NAGly 13:0/11:0

NAGly 13:0/11:0

C26H49NO5 (455.3611)


   

NAGly 11:0/13:0

NAGly 11:0/13:0

C26H49NO5 (455.3611)


   

NAGly 12:0/12:0

NAGly 12:0/12:0

C26H49NO5 (455.3611)


   

NAGly 14:0/10:0

NAGly 14:0/10:0

C26H49NO5 (455.3611)


   

Cer 8:0;3O/18:2;(2OH)

Cer 8:0;3O/18:2;(2OH)

C26H49NO5 (455.3611)


   

Cer 12:1;3O/14:1;(2OH)

Cer 12:1;3O/14:1;(2OH)

C26H49NO5 (455.3611)


   

Cer 10:0;3O/16:2;(2OH)

Cer 10:0;3O/16:2;(2OH)

C26H49NO5 (455.3611)


   

Cer 13:1;3O/13:1;(2OH)

Cer 13:1;3O/13:1;(2OH)

C26H49NO5 (455.3611)


   

(Z)-N-(1,3,4-trihydroxytetradecan-2-yl)tridec-8-enamide

(Z)-N-(1,3,4-trihydroxytetradecan-2-yl)tridec-8-enamide

C27H53NO4 (455.3974)


   

N-[(E)-1,3,4-trihydroxypentadec-8-en-2-yl]dodecanamide

N-[(E)-1,3,4-trihydroxypentadec-8-en-2-yl]dodecanamide

C27H53NO4 (455.3974)


   

(Z)-N-(1,3,4-trihydroxypentadecan-2-yl)dodec-5-enamide

(Z)-N-(1,3,4-trihydroxypentadecan-2-yl)dodec-5-enamide

C27H53NO4 (455.3974)


   

N-[(E)-1,3,4-trihydroxytetradec-8-en-2-yl]tridecanamide

N-[(E)-1,3,4-trihydroxytetradec-8-en-2-yl]tridecanamide

C27H53NO4 (455.3974)


   

Cer 14:2;3O/12:0;(2OH)

Cer 14:2;3O/12:0;(2OH)

C26H49NO5 (455.3611)


   

Cer 14:1;2O/13:0;(3OH)

Cer 14:1;2O/13:0;(3OH)

C27H53NO4 (455.3974)


   

Cer 14:0;2O/13:1;(3OH)

Cer 14:0;2O/13:1;(3OH)

C27H53NO4 (455.3974)


   

Cer 14:0;2O/13:1;(2OH)

Cer 14:0;2O/13:1;(2OH)

C27H53NO4 (455.3974)


   

Cer 15:0;2O/12:1;(2OH)

Cer 15:0;2O/12:1;(2OH)

C27H53NO4 (455.3974)


   

Cer 15:1;2O/12:0;(3OH)

Cer 15:1;2O/12:0;(3OH)

C27H53NO4 (455.3974)


   

Cer 14:1;3O/12:1;(2OH)

Cer 14:1;3O/12:1;(2OH)

C26H49NO5 (455.3611)


   

Cer 14:1;2O/13:0;(2OH)

Cer 14:1;2O/13:0;(2OH)

C27H53NO4 (455.3974)


   

Cer 15:0;2O/12:1;(3OH)

Cer 15:0;2O/12:1;(3OH)

C27H53NO4 (455.3974)


   

Cer 15:1;2O/12:0;(2OH)

Cer 15:1;2O/12:0;(2OH)

C27H53NO4 (455.3974)


   

oscr#35(1-)

oscr#35(1-)

C26H47O6 (455.3372)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#35, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

O-Icosanoylcarnitine

O-Icosanoylcarnitine

C27H53NO4 (455.3974)


An O-acylcarnitine having icosanoyl (arachidoyl) as the acyl substituent.

   

ascr#35(1-)

ascr#35(1-)

C26H47O6 (455.3372)


Conjugate base of ascr#35

   

CarE(20:0)

CarE(20:0)

C27H53NO4 (455.3974)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   

NA-PABA 22:2(13Z,16Z)

NA-PABA 22:2(13Z,16Z)

C29H45NO3 (455.3399)


   

NA-Phe 20:2(11Z,14Z)

NA-Phe 20:2(11Z,14Z)

C29H45NO3 (455.3399)


   
   
   
   

Cer 14:1;O2/13:0;2OH

Cer 14:1;O2/13:0;2OH

C27H53NO4 (455.3974)


   

Cer 14:1;O2/13:0;3OH

Cer 14:1;O2/13:0;3OH

C27H53NO4 (455.3974)


   

Cer 14:1;O2/13:0;O

Cer 14:1;O2/13:0;O

C27H53NO4 (455.3974)


   

Cer 15:1;O2/12:0;2OH

Cer 15:1;O2/12:0;2OH

C27H53NO4 (455.3974)


   

Cer 15:1;O2/12:0;3OH

Cer 15:1;O2/12:0;3OH

C27H53NO4 (455.3974)


   

Cer 15:1;O2/12:0;O

Cer 15:1;O2/12:0;O

C27H53NO4 (455.3974)


   

Cer 16:1;O2/11:0;2OH

Cer 16:1;O2/11:0;2OH

C27H53NO4 (455.3974)


   

Cer 16:1;O2/11:0;3OH

Cer 16:1;O2/11:0;3OH

C27H53NO4 (455.3974)


   

Cer 16:1;O2/11:0;O

Cer 16:1;O2/11:0;O

C27H53NO4 (455.3974)


   

Cer 17:1;O2/10:0;2OH

Cer 17:1;O2/10:0;2OH

C27H53NO4 (455.3974)


   

Cer 17:1;O2/10:0;3OH

Cer 17:1;O2/10:0;3OH

C27H53NO4 (455.3974)


   

Cer 17:1;O2/10:0;O

Cer 17:1;O2/10:0;O

C27H53NO4 (455.3974)


   

Cer 18:1;O2/9:0;2OH

Cer 18:1;O2/9:0;2OH

C27H53NO4 (455.3974)


   

Cer 18:1;O2/9:0;3OH

Cer 18:1;O2/9:0;3OH

C27H53NO4 (455.3974)


   

Cer 18:1;O2/9:0;O

Cer 18:1;O2/9:0;O

C27H53NO4 (455.3974)


   

Cer 14:0;O2/13:1;O

Cer 14:0;O2/13:1;O

C27H53NO4 (455.3974)


   

(1s,2r,5r,7s,9s,11r,13s,17r)-5-{[(4ar,5r,7s,8as)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecane

(1s,2r,5r,7s,9s,11r,13s,17r)-5-{[(4ar,5r,7s,8as)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecane

C30H53N3 (455.4239)


   

1-{1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl}-3-{13-isopropyl-1-methyl-11-azapentacyclo[8.5.0.0²,¹².0³,⁷.0⁷,¹¹]pentadecan-2-yl}propan-1-one

1-{1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl}-3-{13-isopropyl-1-methyl-11-azapentacyclo[8.5.0.0²,¹².0³,⁷.0⁷,¹¹]pentadecan-2-yl}propan-1-one

C29H45NO3 (455.3399)


   

(1r,2r,3as,3bs,7s,9ar,9bs,11as)-7-hydroxy-9a,11a-dimethyl-1-[(1s)-1-[(5r)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl acetate

(1r,2r,3as,3bs,7s,9ar,9bs,11as)-7-hydroxy-9a,11a-dimethyl-1-[(1s)-1-[(5r)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl acetate

C29H45NO3 (455.3399)


   

(1s,2r,4as,8ar)-1-[(3e)-5-(6-imino-1,3-dimethyl-2h-purin-7-yl)-3-methylpent-3-en-1-yl]-1,2,5,5-tetramethyl-hexahydro-2h-naphthalen-4a-ol

(1s,2r,4as,8ar)-1-[(3e)-5-(6-imino-1,3-dimethyl-2h-purin-7-yl)-3-methylpent-3-en-1-yl]-1,2,5,5-tetramethyl-hexahydro-2h-naphthalen-4a-ol

C27H45N5O (455.3624)


   

(1s,2r,5s,7s,9s,11r,13s,17r)-5-{[(4as,5r,7s,8ar)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecane

(1s,2r,5s,7s,9s,11r,13s,17r)-5-{[(4as,5r,7s,8ar)-1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl]methyl}-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecane

C30H53N3 (455.4239)


   

7-hydroxy-9a,11a-dimethyl-1-[1-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl acetate

7-hydroxy-9a,11a-dimethyl-1-[1-(5-methyl-3,4,5,6-tetrahydropyridin-2-yl)ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl acetate

C29H45NO3 (455.3399)


   

1-[5-(6-imino-1,3-dimethyl-2h-purin-7-yl)-3-methylpent-3-en-1-yl]-1,2,5,5-tetramethyl-hexahydro-2h-naphthalen-4a-ol

1-[5-(6-imino-1,3-dimethyl-2h-purin-7-yl)-3-methylpent-3-en-1-yl]-1,2,5,5-tetramethyl-hexahydro-2h-naphthalen-4a-ol

C27H45N5O (455.3624)


   

5-[(1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl)methyl]-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecane

5-[(1-ethyl-7-methyl-octahydro-2h-quinolin-5-yl)methyl]-11,14-dimethyl-6,14-diazatetracyclo[7.6.2.0²,⁷.0¹³,¹⁷]heptadecane

C30H53N3 (455.4239)


   

(15z)-n-benzyltetracos-15-enimidic acid

(15z)-n-benzyltetracos-15-enimidic acid

C31H53NO (455.4127)


   

1-[(1r,4r,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-[(1r,2r,3r,7s,10s,12s,13r)-13-isopropyl-1-methyl-11-azapentacyclo[8.5.0.0²,¹².0³,⁷.0⁷,¹¹]pentadecan-2-yl]propan-1-one

1-[(1r,4r,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-[(1r,2r,3r,7s,10s,12s,13r)-13-isopropyl-1-methyl-11-azapentacyclo[8.5.0.0²,¹².0³,⁷.0⁷,¹¹]pentadecan-2-yl]propan-1-one

C29H45NO3 (455.3399)


   

(1s,2s,7s,10r,11s,14s,15r,16s,17s,18s,20s,23s)-7-hydroxy-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-18-yl acetate

(1s,2s,7s,10r,11s,14s,15r,16s,17s,18s,20s,23s)-7-hydroxy-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-18-yl acetate

C29H45NO3 (455.3399)


   

(6r,9s,13r)-5',7,9,13-tetramethyl-5-oxaspiro[pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,2'-piperidin]-18-en-16-yl acetate

(6r,9s,13r)-5',7,9,13-tetramethyl-5-oxaspiro[pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,2'-piperidin]-18-en-16-yl acetate

C29H45NO3 (455.3399)


   

n-benzyltetracos-15-enimidic acid

n-benzyltetracos-15-enimidic acid

C31H53NO (455.4127)


   

(1r,3as,3bs,5as,7s,9ar,9bs,11as)-1-{1-[(2r,3r,7s)-2,7-dimethyl-1-oxa-5-azaspiro[2.5]oct-4-en-4-yl]ethyl}-7-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one

(1r,3as,3bs,5as,7s,9ar,9bs,11as)-1-{1-[(2r,3r,7s)-2,7-dimethyl-1-oxa-5-azaspiro[2.5]oct-4-en-4-yl]ethyl}-7-hydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-5-one

C29H45NO3 (455.3399)


   

(1r,2r,3as,3bs,7s,9as,9bs,11as)-7-hydroxy-9a,11a-dimethyl-1-[(1s)-1-[(5r)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl acetate

(1r,2r,3as,3bs,7s,9as,9bs,11as)-7-hydroxy-9a,11a-dimethyl-1-[(1s)-1-[(5r)-5-methyl-3,4,5,6-tetrahydropyridin-2-yl]ethyl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-2-yl acetate

C29H45NO3 (455.3399)


   

7-hydroxy-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-18-yl acetate

7-hydroxy-10,14,16,20-tetramethyl-22-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²³.0¹⁷,²²]tetracos-4-en-18-yl acetate

C29H45NO3 (455.3399)


   

1-[(1s,4s,5r)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-[(1s,2s,3r,7s,10r,12r,13s)-13-isopropyl-1-methyl-11-azapentacyclo[8.5.0.0²,¹².0³,⁷.0⁷,¹¹]pentadecan-2-yl]propan-1-one

1-[(1s,4s,5r)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-[(1s,2s,3r,7s,10r,12r,13s)-13-isopropyl-1-methyl-11-azapentacyclo[8.5.0.0²,¹².0³,⁷.0⁷,¹¹]pentadecan-2-yl]propan-1-one

C29H45NO3 (455.3399)